Primary trapeziectomy with RegjointTM, a poly-L/D-lactide spacer, a two-year follow-up study with new radiological assessment tool


Poly-L/D-lactide (PLDLA),osteoarthitis, trapezometacarpal, trapeziectomy, thumb

Published online: Aug 12 2023

Svetlana BOGAERT1, Nicolas CUYLITS2, Konstantinos DROSSOS2, Anne LEJEUNE2, Monika TOOULOU3, Nader CHAHIDI2

1 Erasme Hospital, Brussels, Belgium
2 Centre médical du Parc, Hand surgery department, Brussels, Belgium
3 CHU Charleroi, Charleroi, Belgium


The aim of this retrospective study was to evaluate the potential bony erosion and the clinical and radiological results of primary trapeziectomy with RegjointTM interposition, in patients with peritrapezial arthritis. Data were recorded on twenty patients over a period of two years (January 2015-December 2016). On average 24 months, patients were reconvened for a post-operative evaluation (subjective evaluation of pain, function and patient satisfaction; clinical evaluation with strength and mobility measures; post-operative X-rays). On X-rays, 2 criteria were evaluated: the bony erosion and the shortening of the thumb column (trapezium+metacarpal height measure, ratio between first and second metacarpal bones, a new radiological assessment tool based on a trapezoid relationship gradation). In most patients, surgery relieved pain and offered good functional results, according to the Quick Disabilities of the Arm, Shoulder and Hand scale. Following surgery, our patients showed a subjective improvement, both in terms of pain and functional results. For plain X-ray, only 3 patients showed an osteolytic lesion (maximum of 2.8 millimeters) on the first metacarpal base. A statistically significant reduction in the thumb column height was generally observed on follow-up X-rays. However, all of these radiologic changes were present without any clinical impact. We show that the RegjointTM spacer is an available alternative in the surgical treatment of peritrapezial arthritis. We did not highlight any significant associated complications, no important adverse tissue reaction or bone erosion, no pain or functional disorder.

Type of study/level of evidence Therapeutic IV.